ArticleOncology and therapy2025

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.

Marina C Garassino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.